MoonLake Immunotherapeutics EBIT

MoonLake Immunotherapeutics (MLTX) currently reports a EBIT of $-190M as of June 2026. That compares with $-140M in the prior-year period — down 39.3% year over year. That is below the sector sector average of $-6.4M. Use the charts on this page to explore MoonLake Immunotherapeutics's EBIT history and peer comparisons.

MoonLake Immunotherapeutics's EBIT decreased from $-140M to $-190M — a 39.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MoonLake Immunotherapeutics's EBIT of $-190M is lower than the its sector sector average of $-6.4M. That is roughly 2865.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

MoonLake Immunotherapeutics reported $-190M in EBIT as of June 2026. That compares with $-140M in the prior-year period — down 39.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-190M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-6.4M. From there, open related valuation or income-statement pages for MoonLake Immunotherapeutics, and consider following MLTX for alerts when major investors trade the stock.